Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy

Iodine-125 (125I) is the most commonly used isotope for prostate brachytherapy (BT). Cesium-131 (131Cs) has a higher dose rate and shorter dose delivery time resulting in decreased duration of acute urinary morbidity. Long-term data suggest excellent oncologic outcomes; it is not known how outcomes compare. A prospective randomized trial comparing the two isotopes was initiated.

Source: Brachytherapy - October 12, 2020 Category: Cancer & Oncology Authors: Brian J. Moran, Antony Koroulakis, Cristina Decesaris, Michelle H. Braccioforte, Neha Amin, Manuj Agarwal Source Type: research